These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Feuerstein JD; Cheifetz AS Gastroenterol Clin North Am; 2014 Sep; 43(3):543-63. PubMed ID: 25110258 [TBL] [Abstract][Full Text] [Related]
8. [Drug-induced liver injury with an autoimmune phenotype following anti-TNF Therapy - presentation of cases and review of literature]. Rösner S; Schad A; Kittner J; Rahman F; Wörns MA; Schuchmann M; Galle PR; Schattenberg JM Z Gastroenterol; 2014 Jan; 52(1):58-63. PubMed ID: 24420801 [TBL] [Abstract][Full Text] [Related]
9. Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab. Parisi I; O'Beirne J; Rossi RE; Tsochatzis E; Manousou P; Theocharidou E; Hamilton M; Murray C; Epstein O; Burroughs AK Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):786-91. PubMed ID: 27015138 [TBL] [Abstract][Full Text] [Related]
10. The role of infliximab on paracetamol-induced hepatotoxicity in rats. Ferah I; Halici Z; Bayir Y; Demirci E; Unal B; Cadirci E Immunopharmacol Immunotoxicol; 2013 Jun; 35(3):373-81. PubMed ID: 23496246 [TBL] [Abstract][Full Text] [Related]
11. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Sokolove J; Strand V; Greenberg JD; Curtis JR; Kavanaugh A; Kremer JM; Anofrei A; Reed G; Calabrese L; Hooper M; Baumgartner S; Furst DE; Ann Rheum Dis; 2010 Sep; 69(9):1612-7. PubMed ID: 20448284 [TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series. Sandhu A; Alameel T; Dale CH; Levstik M; Chande N Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981 [TBL] [Abstract][Full Text] [Related]
13. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. Lopetuso LR; Mocci G; Marzo M; D'Aversa F; Rapaccini GL; Guidi L; Armuzzi A; Gasbarrini A; Papa A Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060508 [TBL] [Abstract][Full Text] [Related]
15. Drug-Induced Liver Injury Used in the Treatment of Inflammatory Bowel Disease. Núñez F P; Quera R; Bay C; Castro F; Mezzano G J Crohns Colitis; 2022 Aug; 16(7):1168-1176. PubMed ID: 35044449 [TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Khokhar OS; Lewis JH Dig Dis; 2010; 28(3):508-18. PubMed ID: 20926880 [TBL] [Abstract][Full Text] [Related]
17. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906 [TBL] [Abstract][Full Text] [Related]
18. Role of the perforin/granzyme cell death pathway in D-Gal/LPS-induced inflammatory liver injury. Kuhla A; Eipel C; Abshagen K; Siebert N; Menger MD; Vollmar B Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1069-76. PubMed ID: 19264954 [TBL] [Abstract][Full Text] [Related]
19. The long-term effects of anti-TNF-α agents on patients with chronic viral hepatitis C and B infections. Temel T; Cansu DÜ; Korkmaz C; Kaşifoğlu T; Özakyol A Int J Rheum Dis; 2015 Jan; 18(1):40-5. PubMed ID: 25195983 [TBL] [Abstract][Full Text] [Related]
20. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Tukov FF; Luyendyk JP; Ganey PE; Roth RA Toxicol Sci; 2007 Nov; 100(1):267-80. PubMed ID: 17698507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]